Detailed description page of ThPDB2

This page displays user query in tabular form.

10694 details
Primary information
ID10694
Therapeutic IDTh1157
Protein NameSermorelin
Sequence>Th1157_Sermorelin YADAIFTNSYRKVLGQLSARKLLQDIMSRQ
Molecular Weight3357.882
Chemical FormulaC149H246N44O42S
Isoelectric Point9.99
Hydrophobicity-0.33
Melting pointNA
Half-life11-12 minutes
DescriptionSermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.
Indication/DiseaseFor the treatment of dwarfism, prevention of HIV-induced weight loss
PharmacodynamicsSermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.
Mechanism of ActionSermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAmino Acids, Peptides, and Proteins,Anterior Pituitary Lobe Hormones and Analogues,Diagnostic Agents,Growth Hormone-Releasing Hormone,Hormones,Hormones, Hormone Substitutes, and Hormone Antagonists,Hypothalamic Hormones,Nerve Tissue Proteins,Neuropeptides,Peptide Hormones,Peptides,Pituitary and Hypothalamic Hormones and Analogues,Pituitary Hormone-Releasing Hormones,Somatropin and Somatropin Agonists,Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins,Tests for Pituitary Function
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetGrowth hormone-releasing hormone receptor
Brand NameSermorelin acetate
CompanyEmd serono inc
Brand DescriptionEmd serono inc
Prescribed ForSermorelin is approved for diagnostic evaluation of pituitary function and also for increasing growth in children. Off label usage may include acute or age-related growth hormone insufficiency
Chemical NameNA
FormulationTwo vial presentations are available, Each vial contains 0.5 mg sermorelin (as the acetate) and 5 mg mannitol. The pH is adjusted with dibasic sodium phosphate and monobasic sodium phosphate buffer. Each vial contains 3.0 mg sermorelin (as the acetate) and 5 mg mannitol. The pH is adjusted with dibasic sodium phosphate and monobasic sodium phosphate buffer.
Physical Appearance Sermorelin is a sterile, non-pyrogenic, lyophilized powder
Route of AdministrationSubcutaneous Injection
Recommended DosageA dosage of 0.2 - 0.3 mcg once daily at bedtime by subcutaneous injection is recommended. It is also recommended that subcutaneous injection sites be periodically rotated.
ContraindicationSermorelin should not be used by patients with a known sensitivity to sermorelin or any of the excipients
Side EffectsThe most common treatment-related adverse event (occurring in about 1 patient in 6) is local injection reaction characterized by pain, swelling or redness. Other treatment-related adverse events had individual occurrence rates of less than 1% and include: headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and urticaria.
Useful Link 1Link
Useful Link 2NA
RemarksNA